Compare UTI & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTI | MGTX |
|---|---|---|
| Founded | 1965 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2003 | 2018 |
| Metric | UTI | MGTX |
|---|---|---|
| Price | $21.28 | $13.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $37.50 | $24.57 |
| AVG Volume (30 Days) | ★ 1.9M | 588.5K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.67 | 33.02 |
| EPS | 0.28 | ★ 1.30 |
| Revenue | ★ $835,616,000.00 | $81,391,000.00 |
| Revenue This Year | $10.15 | $141.38 |
| Revenue Next Year | $8.32 | N/A |
| P/E Ratio | $77.21 | ★ $10.88 |
| Revenue Growth | 14.05 | ★ 144.57 |
| 52 Week Low | $21.29 | $6.62 |
| 52 Week High | $51.34 | $15.35 |
| Indicator | UTI | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 27.27 | 55.37 |
| Support Level | $21.29 | $7.04 |
| Resistance Level | $26.98 | $15.35 |
| Average True Range (ATR) | 1.30 | 0.76 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 4.20 | 53.08 |
Universal Technical Institute Inc is an educational institution. It provides undergraduate degree, as well as certificate programs for technicians in the automotive, diesel, collision repair, motorcycle and marine fields. The company's reportable segment which includes Universal Technical Institute (UTI) and Concorde Career Colleges, Corporate. Majority of the revenue is generated from UTI segment which provides different kinds of degree and non-degree transportation and skilled trades technical training programs under brands such as Universal Technical Institute, Motorcycle Mechanics Institute, Marine Mechanics Institute and others. It also provides dealer technician training or instructor staffing services to manufacturers.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.